Self-reported clinical characteristics of participants prior to screening
| Clinical characteristics | Participants, N=1338 |
| Age, median (IQR), years | 69.0 (67.0–71.0) |
| Body mass index, median (IQR), kg/m2 | 27.3 (25.0–30.3) |
| Self-reported conditions, n (%) | |
| AF* | 106 (7.9) |
| Diabetes | 146 (10.9) |
| Hypertension | 567 (42.4) |
| Ischaemic stroke | 81 (6.1) |
| Acute myocardial infarction | 83 (6.2) |
| Peripheral arterial disease | 30 (2.2) |
| CABG or PCI | 11 (8.3) |
| Chronic obstructive pulmonary disease | 91 (6.8) |
| Smoking, n (%) | |
| Never | 451 (33.9) |
| Former | 687 (51.6) |
| Current | 193 (14.5) |
| Medication, n (%) | |
| Antiplatelets | 318 (23.8) |
| OAC for any indication† | 114 (8.5) |
| Statins | 476 (35.6) |
| Antiarrhythmic drug | 14 (1.1) |
| Thiazide | 55 (4.1) |
| Beta-antagonists | 207 (15.5) |
| ACE inhibitor/ARB | 484 (36.2) |
| Ca++ antagonist | 265 (19.8) |
| Potassium-sparing diuretics | 79 (5.9) |
Missing data, n (%): body mass index 1 (0.07), AF 4 (0.3) and smoking 7 (0.5).
*As informed by the general practitioner or during hospitalisation.
†The use of warfarin, novel OACs or phenprocoumon for any indication, for example, AF, venous thromboembolism or mechanical heart valves.
AF, atrial fibrillation; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; OAC, oral anticoagulation; PCI, percutaneous coronary intervention.